A total 62 patients were recruited. The MTD was defined as 125 mg/day BGJ in combination with 300 mg/day Alp based on 32 patients’ data obtained during dose escalation. DLTs were seen in 4 patients. 24 patients were enrolled in the expansion cohort. At the MTD, 61% of patients had ≥1 BGJ/Alp dose reduction. 8 patients had PRs, out of which 4 patients were confirmed but with different cancers. One patient with FGFR3-TACC3 fusion urothelial carcinoma had a PR and a complete shrinkage lasting 4 months. The gene discussed is TACC3; the disease is urothelial carcinoma.